WO1999019297A1 - Synthesis of azetidine derivatives - Google Patents

Synthesis of azetidine derivatives Download PDF

Info

Publication number
WO1999019297A1
WO1999019297A1 PCT/US1998/021786 US9821786W WO9919297A1 WO 1999019297 A1 WO1999019297 A1 WO 1999019297A1 US 9821786 W US9821786 W US 9821786W WO 9919297 A1 WO9919297 A1 WO 9919297A1
Authority
WO
WIPO (PCT)
Prior art keywords
reaction
product
added
group
compound
Prior art date
Application number
PCT/US1998/021786
Other languages
English (en)
French (fr)
Other versions
WO1999019297A9 (en
Inventor
Zhengming Chen
Hartmuth C. Kolb
Paul Richardson
Zhi-Min Huang
Original Assignee
Coelacanth Chemical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coelacanth Chemical Corporation filed Critical Coelacanth Chemical Corporation
Priority to AU10895/99A priority Critical patent/AU1089599A/en
Publication of WO1999019297A1 publication Critical patent/WO1999019297A1/en
Publication of WO1999019297A9 publication Critical patent/WO1999019297A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to building blocks for the creation of a high degree of structural diversity among compounds within a combinatorial library.
  • compounds that may serve as building blocks and methods for generating such compounds.
  • Combinatorial chemistry refers to techniques for creating a multiplicity of compounds, referred to as a "library”, and then testing the library or each member of the library for biological activity. In recent years, combinatorial chemistry has become an important tool for the drug discovery efforts of many pharmaceutical companies.
  • a "building block” is a reagent or compound which can combine (i.e., react) with one or more other reagents to yield the compounds which, together, form a combinatorial library.
  • building block is a reagent or compound which can combine (i.e., react) with one or more other reagents to yield the compounds which, together, form a combinatorial library.
  • the present invention provides a compound having the formula:
  • R, Ri , R are independently selected from the group consisting of hydrogen, Cj-C ⁇ lower alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 2 -C 6 alkylcarbonyl, C 3 -C 6 cycloalkyl, trifluoromethylcarbonyl, or (CH ) n - ⁇ henyl or -(CH 2 ) n - heteroaryl where n is 0 to 4 and where the phenyl or the heteroaryl is optionally substituted with 1 to 3 halogens, C ⁇ -C 6 lower alkyl, C ⁇ -C 6 alkoxy, C 2 -C 6 alkylcarbonyl, carboxy, or C ⁇ -C 6 carboxyalkyl; aryl or heteroaryl carbonyl which may be optionally substituted with 1 to 3 halogens, C ⁇ -C 6 lower alkyl, C]-C 6 alkoxy, C 2 -C 6 alkyl
  • n 1, 2, or 3
  • W is N, CH, or O, provided that when W is O, R 3 does not exist;
  • R 3 is hydrogen, C ⁇ -C 6 lower alkyl, C 2 -C 6 alkenyl, C -C 6 alkynyl, C -C 6 alkylcarbonyl, C -C 6 cycloalkyl, carboxy, C 2 -C 6 alkoxycarbonyl, aryl or heteroaryl, each of which is optionally mono-, di-, or trisubstituted with straight or branched chain lower alkyl having 1 to 6 carbon atoms, halogen, trifluoromethyl, hydroxy, straight or branched chain lower alkenyl having 2 to 6 carbon atoms, trifluormethoxy, or amino, dialkylamino having 2 to 6 carbon atoms, -CO 2 R where R is alkyl having 1-6 carbon atoms, -(CH ) m -O-R 5 where m is 1-6 and R 5 is hydrogen or lower alkyl having 1-6 carbon atoms.
  • the present invention provides building blocks for combinatorial libraries.
  • the present invention provides a composition comprising a compound having structural formula I as defined above in combination with a acceptable carrier.
  • the present invention relates to building blocks for the synthesis of a collection of compounds as a combinatorial library.
  • a "collection of compounds” comprises at least three different compounds, also referred to as the "disclosed building blocks" or the "member compounds".
  • the collection comprises at least five different compounds, more preferably at least thirty different compounds.
  • the collection comprises at least fifty different compounds.
  • Each of the disclosed building blocks is: 1) substantially pure; 2) is substantially free of contamination by the other building herein; and 3) contains at least one reactive group.
  • a building block can contain one or more non- reactive functional groups.
  • substantially pure means, for example, that the disclosed building block is at least about 80% pure, and preferably at least about 90% pure and more preferably at least about 95% pure.
  • substantially free of contamination by other members of the collection means, for example, that the disclosed building block contains less than 5% of the other building blocks in the collection and more preferably less than 1.0% of the other building blocks in the collection, and even more preferably less than 0.1% of the other building blocks in the collection.
  • a “reactive functional group” allows the compound in the collection to be reacted directly with other reagents or compounds to form a member of a combinatorial library or a precursor thereof. "Reacted directly” means, for example, that the reactive functional group can react and form covalent bonds with the other compounds without the need of intervening reactions such as a deprotection reaction.
  • the reactive functional group determines the interconnection chemistries, i.e., the manner in which the disclosed building block can be reacted with other building blocks of the combinatorial library.
  • reactive functional groups include a hydroxyl group, a primary amine group, a secondary amine group, a thiol, a carboxylic acid, an ester, an aldehyde, an azide, a nitrile, an isonitrile, an epoxide, an aziridine, an isocyanate, a thioisocyanate and a halide.
  • non-reactive functional group is inert under the reaction conditions employed for interconnecting the disclosed building blocks with other building blocks used to prepare a member of a combinatorial library or a precursor thereof, unless the non-reactive functional group is, for example, first activated or undergoes a deprotection reaction.
  • non-reactive functional groups include an ether, a thioether, a tertiary amine, an alkene, an alkyne, an alkoxycarbonyl, a ketal or an acetal.
  • a member compound has at least one reactive functional group. More than one reactive functional group can be present in a member compound, provided that the reactivity of each reactive functional group is orthogonal to the reactivities of the other functional groups, i.e., each reactive functional group can selectively react in the presence of the others.
  • a reactive functional group can be introduced into the building block or member compound by, for example, formation of a carbon-heteroatom bond between a precursor compound and a reagent. Specific examples are provided in the following paragraphs.
  • the formation of a carbon-heteroatom bond between a precursor compound and a reagent can occur by reacting an electrophilic precursor compound and a nucleophilic reagent.
  • a reactive functional group which can be introduced by this type of transformation is a secondary amine R'NH-, which is formed from the reaction of an electrophilic precursor compound and R 1 NH 2 , or the anion thereof (or by the reaction of a carbonyl group with a primary amine under reducing conditions).
  • RI is an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group.
  • R ' is an aliphatic or aromatic group substituted with at least one reactive functional group.
  • nucleophilic reagent for this type of transformation is R ⁇ R IV NH, or the anion thereof, wherein R I ⁇ and R IV , together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic ring or is substituted with a reactive functional group.
  • the reaction of this nucleophilic reagent with an electrophilic precursor can introduce R ' R N- into a member compound.
  • Examples of other reactive functional groups which can be introduced into a member compound include H 2 N-, HO-, C1-, Br-, I-, CN-, N 3 -, NC-, which are formed by the reaction of a suitable electrophilic precursor compound with NH (or NH 2 " ), H 2 O (or OH “ ), Cl “ , Br “ , T, CN “ , N 3 “ , and trimethylsily cyanide, respectively.
  • the nucleophile can also be a part of the elecrophilic precursor, i.e., the reaction is intramolecular, respectively.
  • the nucleophile can also be part of the electrophilic precursor, i.e., the reaction is intramolecular.
  • Epoxides and aziridines are examples of reactive functional groups formed in this manner.
  • suitable electrophilic precursors which can be used to introduce reactive functional groups into a building block by reaction with a nucleophilic reagent include alkyl halies, aryl halides, alkyl sulfates, alkyl sulfonates, epoxides and aziridines.
  • a reactive functional group can also be formed by converting a reactive functional group present in a member compound to a different reactive group.
  • This type of reaction is the conversion of a primary amine to isocyanate by reaction with phosgene or Cl-COO-C(CL ) or the replacement of a halide with an amine.
  • a reactive functional group can be formed by removing a protecting group present in a member compound. Examples include cleaving a tert- butoxycarbonyl group (hereinafter "BOC”) to regenerate a free primary or secondary amine or hydrolyzing an acetal or ketal to liberate an aldehyde or ketone, respectively.
  • BOC tert- butoxycarbonyl group
  • the formation of a carbon-heteratom bond between a precursor compound and reagent can also occur by reacting a nucleophilic precursor compound, e.g., a compound containing one or more double and/or triple bonds, and an electrophilic reagent.
  • a nucleophilic precursor compound e.g., a compound containing one or more double and/or triple bonds
  • an electrophilic reagent e.g., -Cl, -Br-, -I, -OH, -O-, -N 3 , and an aziridine
  • an aziridine can be formed by reacting a compound containing one or more double and/or triple bonds with, for example, SC1 2 , RSC1, SBr 2 , SI , N-bromosuccinimide, meta-chloroperbenzoic acid, NaN3 or tosyl chloramine.
  • a non-reactive functional group can be introduced into a building block or member compound by formation of a carbon-heteroatom bond between a precursor compound and a reagent, for example, by reacting an electrophilic precursor compound and a neucleophilic reagent.
  • electrophilic precursor compounds are as described above for introducing reactive functional groups into building blocks.
  • suitable nucleophilic reagents for introducing non- reactive functional groups into a building block include R V R V1 NH, R V SH, R v OH, or the anions thereof.
  • R and R VI are independently an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group.
  • Substituted aliphatic and substituted aromatic groups represented by R v and R VI can contain non- reactive functional groups but no reactive functional groups.
  • These nucleophilic reagents, together with a suitable electrophilic precursor compound, can be used to introduce R V R V1 N-, R V S- and R v OH, respectively into a building block.
  • Another example of a suitable necleophilic reagent for introducing a non-reactive functional group into the building block is R VI, R VIII NH, or the anion thereof.
  • R v " and R v ⁇ together with the nitrogen atom to which they are bonded, form a non-aromatic heterocyclic group which does not contain -NH- in the non-aromatic heterocyclic ring and is not substituted with a reactive functional group.
  • R VII R VII1 NH or its anion and a suitable eletrophilic precursor compound R V1I R VIII N- can be introduced into a building block.
  • a suitable nucleophilic reagent for introducing a non-reactive functional group into a building block is R VI NH 2 , or the anion thereof. Use of this reagent and a precursor molecular having at least to electrophilic sites results in the formation of a non-reactive R IV N ⁇ functional group.
  • the disclosed building blocks can be formed from virtually any combination of the eletrophilic precursor compounds and the nucleophilic reagents which are disclosed herein or from the nucleophilic precursor compounds (e.g., compounds containing one or more units of unsaturation) and the electrophilic reagents which are disclosed herein, provided that at least one reactive group is present in the building block.
  • the collection includes building block.
  • the collection includes building blocks which are formed from an electrophilic precursor compound and a nucleophilic reagent disclosed herein or from a nucleophilic precursor compound containing one or more units of unsaturation and an electrophilic reagent disclosed herein.
  • the collection consists of building blocks from an electrophilic precursor compound and a nucleophilic reagent disclosed herein or from a nucleophilic precursor compound containing one or more units of unsaturation and an electrophilic reagent disclosed herein.
  • the collection includes the building blocks disclosed herein.
  • the collection consists of the building blocks disclosed herein.
  • novel compounds encompassed by the instant invention can be described by the general Formula I set forth above or the pharmaceutically acceptable non-toxic salts thereof.
  • the present invention provides a compound of
  • R, Ri, R 2 are independently selected from the group consisting of hydrogen, C ⁇ -C 6 lower alkyl, C -C 6 alkylcarbonyl, trifluoromethylcarbonyl, or
  • (CH ) n -phenyl where n is 0 to 4 and where the phenyl is optionally substituted with halogen, C ⁇ -C 6 lower alkyl, C]-C 6 carboxy, C 2 -C 6 alkylcarbonyl; in addition, Ri and R , together with the nitrogen to which each is attached, may form azide or a structure shown below:
  • a compound of Formula I has R is selected from CH -phenyl, H, t-butyl,
  • a compound of Formula I wherein R is CH 2 -phenyl and wherein Rj, R and the N to which each is attached form azide or a structure selected from:
  • R is hydrogen and wherein R 1 ⁇ R 2 and the N to which each is attached form a structure selected from:
  • a compound of Formula I where R is t- butyl and where Ri, R and the N to which each is attached form one of the following structures:
  • R is
  • the most preferred compounds include the following and their pharmaceutically acceptable salts: 2-methoxyphenylpiperazine; l-(2-pyridyl)- piperazine; 1-pyrimidylpiperazine; 1-phenylpiperazine; 1-methylpiperazine; morpholine; piperidine; pyrrolidine; dimethylamine; methylamine; isopropylamine; methallyamine; sodium azide; azetidin-3-ol; 2-methoxyphenlpiperazine; 1(2- hydroxyethyl)-piperazine; piperazine; 1 -tert-butoxycarbonyl perhydrodiazepine; 1- methylpiperazine; 1-phenylpiperazine; 1-pyrimidylpiperazine; 4- fluorophenylpiperazine; 4-methoxyphenylpiperazine; 4-methylphenylpiperazine; 4- trifluoromethoxyphenylpiperazine; 4-trifluoromethylphenylpiperazine; 1 -(2-pyridy
  • Alkyl means a straight or branched hydrocarbon radical having from 1 to 10 carbon atoms (unless stated otherwise; preferably C]-C 6 ) and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, and the like.
  • Halo includes fluoro, chloro, bromo, and iodo.
  • Alkenyl means straight and branched hydrocarbon radicals having from 2 to 10 carbon atoms and one double bond and includes ethenyl, 3-buten-l-yl, 2-ethenylbutyl, 3-hexen-l-yl, and the like.
  • Alkynyl means straight and branched hydrocarbon radicals having from 2 to
  • C 2 -C ⁇ 0 alkynyl groups include propynyl, 2-butyn-l-yl, 3-pentyn-l-yl, and the like.
  • Cycloalkyl means a cyclic hydrocarbyl group such as cyclopropyl, cyclobutyl, cyclohexyl, and cyclopentyl, and the like.
  • Alkoxy refers to the alkyl groups mentioned above bound through a single oxygen atom, examples of which include methoxy, ethoxy, isopropoxy, tert-butoxy, and the like.
  • Carboalkoxy refers to an organic acid esterified with a lower alcohol or amidated with an amine, respectively. Such groups include, for example,
  • Alkanoyl or alkylcarbonyl groups are alkyl as previously defined linked through a carbonyl, i.e., C ⁇ -C ⁇ o-C(O)- or C 2 -C 6 -C(O)-.
  • Such groups include formyl, acetyl, propionyl, butyryl, and isobutyryl.
  • acyl includes a Ci-Cio alkanoyl, including substituted alkanoyl, wherein the alkyl portion can be substituted by NR'R" or a carboxylic or heterocyclic group.
  • Typical acyl groups include acetyl, benzoyl, and the like.
  • alkyl, alkenyl, alkoxy, and alkynyl groups described above are optionally substituted by N, NR, phenyl, substituted phenyl, thio, Ci-Cio alkyl (preferably
  • Ci-Cio alkoxy (preferably C ⁇ -C 6 ), hydroxy, carboxy, -Cio alkoxycarbonyl
  • substituted nitrogen means nitrogen bearing Cr o alkyl (preferably C ⁇ -C 6 ) or (CH ) n Ph where n is 1, 2, or 3.
  • substituted alkyl groups examples include 2-aminoethyl,
  • substituted alkynyl groups examples include 2-methoxyethynyl,
  • Typical substituted alkoxy groups include aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 3 -diethylamino-2-hydroxy-propoxy, 2-ethoxycarbonylethoxy, 3-hydroxypropoxy, 6-carboxhexyloxy, and the like.
  • substituted alkyl, alkenyl, and alkynyl groups include dimethylaminomethyl, carboxymethyl, 4-dimethylamino-3-buten-l-yl,
  • aliphatic groups comprise straight chained, branched or cyclic C ⁇ -C 8 hydrocarbons which are completely saturated or which contain one or more units of unsaturation.
  • Suitable substituents for an aliphatic group or an aromatic group comprise reactive functional groups and non-reactive functional groups, as described above.
  • Heteroaryl groups are aryls having from 4 to 9 ring atoms, from 1 to 4 of which are independently selected from the group consisting of O, S, and N. Mono and bicyclic aromatic ring systems are included in the definition of aryl and heteroaryl.
  • Typical aryl and heteroaryl groups include phenyl, 3-chlorophenyl, 2,6-dibromophenyl, pyridyl, 3-methylpyridyl, benzothienyl, 2,4,6-tribromophenyl, 4-ethylbenzothienyl, furanyl, 3,4-diethylfuranyl, naphthyl, 4,7-dichloronaphthyl, benzofuranyl, indoyl, and the like.
  • Aromatic groups may also comprise carbocyclic aromatic groups such as phenyl, 1 -naphthyl, 2-naphthyl, 1-anthracyl and 2-anthacyl, and heterocyclic aromatic groups such as N-imidazolyl, 2-imidazole, 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidy, 4-pyrimidyl, 2-pyranyl, 3-pyranyl, 3- pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-pyrazinyl, 2-thiazole, 4-thiazole, 5-thiazole, 2- oxazolyl, 4-oxazolyl and 5-oxazolyl.
  • carbocyclic aromatic groups such as phenyl, 1 -naphthyl, 2-naphthyl, 1-anthracyl and 2-anthacyl
  • aromatic groups may comprise fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings.
  • Examples include 2-benzothienyl, 3 -benzothienyl, 2- benzofuranyl, 3-benzofuranyl, 2-indolyl, 3-indolyl, 2-quinolinyl, 3-quinolinyl, 2- benzothiazole, 2-benzooxazole, 2-benzimidazole, 2-quinolinyl, 3-quinolinyl, 2- benzothiazole, 2-benzooxazole, 2-benzimidazole, 2-quinolinyl, 3-quinolinyl, 1- isoquinolinyl, 3-quinolinyl, 1-isoindolyl, 3-isoindolyl, and acridinyl.
  • Preferred Ar groups are phenyl and substituted phenyl.
  • the alkyl and alkoxy groups can be substituted as defined herein.
  • typical groups are carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, hydroxyalkoxy, and alkoxyalkyl.
  • the compounds of the instant invention may be prepared using the chemical synthesis described below:
  • the starting azetidinols may be prepared utilizing a modified procedure of Gaertner (J. Org. Chem., 1967, 32. 2972) according to the following sequence:
  • mesylation is carried out at low temperature to minimize side reactions; mesylate is used immediately to prevent decomposition; the displacement reaction is carried out in water; and, by-products are easily removed (a feature of ClickchemTM).
  • the product crashes out of solution (particularly in the case of aromatic nucleophiles were a slight excess of the mesylate is employed).
  • use of the tert-butyl group leads to a cleaner displacement reaction thus leading to a more easily purifiable product.
  • the majority of known studies on substituted azetidines have avoided benzyl as the protecting group, and have instead used benzhydryl (Chatterjee, et al. Synthesis, 1973, 153).
  • Acylative dealkylation is also contemplated by the instant invention.
  • the procedure using acetic anhydride was developed by Dave (J. Org. Chem., 1996, 61, 5453), though its use was limited to three substrates due probably to difficulty in isolating the products.
  • the present invention solves certain difficulties associated with the method of Dave by: using a co-solvent; providing a modified work-up that makes product isolation easier; extend the scope of the process of Dave to a number of new substrates; and, providing an improved method for hydrolysis of the amide bond using hydrogen chloride gas in ethanol.
  • the present invention also extends the scope of the acylative dealkylation method, and provides a method that allows the deprotection of acid sensitive compounds. For instance, several of the substrates in the current study contain acid- sensitive functional groups and cannot, therefore, be deprotected by either of the methods described above.
  • the instant invention provides a new method for the cleavage of the tert-butyl group in these systems (Nussbaumer, et al., Tetrahedron, 1991, 47, 4591). As with the acetic anhydride method, the instant invention provides a two step method first involving formation of the trifluoroacetamide followed by cleavage under basic conditions.
  • the advantages of the instant invention include: the reaction takes place at 0°C; only slightly more than a stoichiometric amount of trifluoroacetic anhydride is required; the reaction is very rapid (with the addition of one equivalent of triethylamine, the reaction is complete within one hour); the work- up is simple; the reaction is very clean, thus simplifying product isolation; amide hydrolysis is also rapid and takes place at room temperature.
  • IL acetonitrile
  • Triethylamine (303.1 g, 3 mol) was added, and the mixture was refluxed for 3 days (a white solid was observed to precipitate from solution within 24 hrs). After being allowed to cool to room temperature, triethylamine hydrochloride was filtered off, and the solid washed with petroleum ether. Removal of the solvent in vacuo gave a yellow oil, which was distilled (oil bath 75 °C) to give the silyl ether (400 g, 95% pure, 97% yield) as a colorless oil (b.p. 45 °C/2-3 mmHg).
  • N-t-butyl-O-trimethylsilylazetidine 400 g, 2 mol was added portionwise to 3 ⁇ Hydrochloric acid solution (733 mL) at room temperature, and the resulting mixture was stirred at ambient temperature. An exothermic reaction took place.
  • N-benzyl-3-methylaminoazetidine (6.0g, 22%o) as a slightly yellow liquid. Further purification can be carried out by distillation (75-78°C/ ImmHg) to afford N-benzyl-3-methylaminoazetidine as a colourless liquid.
  • the hydrochloride salt (185g, 0.41mol) was dissolved in methanol (IL), and palladium hydroxide (21g, 20% on carbon) was added.
  • the bottle was evacuated, and then pressurised under hydrogen (40psi) and shaken whilst being heated to 60°C. On reaching the desired temperature, the pressure was increased to ⁇ Opsi, and shaking continued for a further 48 hours (during this time the hydrogen pressure was recharged twice).
  • the heater was then turned off, and the reaction allowed to cool to room temperature under hydrogen. After the hydrogen pressure had been released, the bottle was then opened, and the reaction was filtered through celite washing with hot methanol (8L) followed by water (3L).
  • the viscous black residue was poured into a mixture of 50% potassium hydroxide (120ml) and ice water (400ml) ensuring the resulting solution is at basic pH. After being allowed to stir for 30 minutes at 0°C, the aqueous solution was extracted with methylene chloride (3 x 600ml). The combined organic extracts were dried over magnesium sulfate, and the solvent removed in vacuo to afford the product as a light brown solid. Purification of the product was carried out by passing it through a pad of silica gel eluting the product with 80 : 10 : 10 ; ethyl acetate : methanol : triethylamine. The product (93g, 70%>) was obtained as a slightly yellow solid.
  • the viscous black residue was poured into a mixture of 50% potassium hydroxide (120ml) and ice water (400ml) ensuring the resulting solution is at basic pH. After being allowed to stir for 30 minutes at 0°C, the aqueous solution was extracted with methylene chloride (3 x 400ml). The combined organic extracts were dried over magnesium sulfate, and the solvent removed in vacuo to afford the product as a light brown solid. Purification of the product was carried out by passing it through a pad of silica gel eluting the product with 80 : 10 : 10 ; ethyl acetate : methanol : triethylamine. The product (83.5g, 74.5%) was obtained as a slightly yellow solid.
  • the viscous black residue was poured into a mixture of 50%> potassium hydroxide (120ml) and ice water (400ml) ensuring the resulting solution is at basic pH. After being allowed to stir for 30 minutes at 0°C, the aqueous solution was extracted with methylene chloride (3 x 600ml). The combined organic extracts were dried over magnesium sulfate, and the solvent removed in vacuo to afford the product as a light brown solid. Purification of the product was carried out by passing it through a pad of silica gel eluting the product with 80 : 10 : 10 ; ethyl acetate : methanol : triethylamine. The product (76g, 83%>) was obtained as a slightly yellow solid.
PCT/US1998/021786 1997-10-15 1998-10-15 Synthesis of azetidine derivatives WO1999019297A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10895/99A AU1089599A (en) 1997-10-15 1998-10-15 Synthesis of azetidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6247097P 1997-10-15 1997-10-15
US60/062,470 1997-10-15

Publications (2)

Publication Number Publication Date
WO1999019297A1 true WO1999019297A1 (en) 1999-04-22
WO1999019297A9 WO1999019297A9 (en) 1999-07-08

Family

ID=22042707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/021786 WO1999019297A1 (en) 1997-10-15 1998-10-15 Synthesis of azetidine derivatives

Country Status (2)

Country Link
AU (1) AU1089599A (de)
WO (1) WO1999019297A1 (de)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063168A1 (en) * 1999-04-16 2000-10-26 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
JP2009523715A (ja) * 2006-01-16 2009-06-25 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺虫剤
US8362001B2 (en) 2009-04-22 2013-01-29 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8415341B2 (en) 2009-04-22 2013-04-09 Janssen Pharmaceutica, Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
US8575363B2 (en) 2010-10-22 2013-11-05 Janssen Pharmaceutica N.V. Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
US8637498B2 (en) 2010-09-27 2014-01-28 Janssen Pharmaceutica, Nv Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
US8759533B2 (en) 2010-09-03 2014-06-24 Janssen Pharmaceutica Nv Di-azetidinyl diamide as monoacylglcerol lipase inhibitors
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2150816A1 (de) * 1971-08-21 1973-04-13 Teikoku Hormone Mfg Co Ltd
EP0155870A1 (de) * 1984-02-27 1985-09-25 Sanofi 3-Amino-azetidin, seine Salze, Verfahren zu deren Herstellung und Zwischenprodukte
EP0406112A1 (de) * 1989-06-29 1991-01-02 Laboratorios Del Dr. Esteve, S.A. 1-Benzhydrylazetidine, deren Herstellung und Verwendung als Zwischenprodukte zur Herstellung von Verbindungen mit antimikrobieller Wirkung
WO1996005193A1 (en) * 1994-08-09 1996-02-22 Pfizer Limited (azetidin-1-ylalkyl)lactams as tachykinin antagonists
WO1997025322A1 (en) * 1996-01-05 1997-07-17 Pfizer Research And Development Company, N.V./S.A. 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
WO1997027185A1 (en) * 1996-01-22 1997-07-31 Pfizer Research And Development Company, N.V./S.A. Piperidone tachykinin antagonists
WO1999001451A1 (en) * 1997-07-04 1999-01-14 Pfizer Limited Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2150816A1 (de) * 1971-08-21 1973-04-13 Teikoku Hormone Mfg Co Ltd
EP0155870A1 (de) * 1984-02-27 1985-09-25 Sanofi 3-Amino-azetidin, seine Salze, Verfahren zu deren Herstellung und Zwischenprodukte
EP0406112A1 (de) * 1989-06-29 1991-01-02 Laboratorios Del Dr. Esteve, S.A. 1-Benzhydrylazetidine, deren Herstellung und Verwendung als Zwischenprodukte zur Herstellung von Verbindungen mit antimikrobieller Wirkung
WO1996005193A1 (en) * 1994-08-09 1996-02-22 Pfizer Limited (azetidin-1-ylalkyl)lactams as tachykinin antagonists
WO1997025322A1 (en) * 1996-01-05 1997-07-17 Pfizer Research And Development Company, N.V./S.A. 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
WO1997027185A1 (en) * 1996-01-22 1997-07-31 Pfizer Research And Development Company, N.V./S.A. Piperidone tachykinin antagonists
WO1999001451A1 (en) * 1997-07-04 1999-01-14 Pfizer Limited Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 83, no. 1, 7 July 1975, Columbus, Ohio, US; abstract no. 9760, SUZUKI Y. ET AL.: "3-Aminoazetidines or their salts" XP002094429 *
V.R. GAERTNER: "Reactions of nucleophiles with 1-tert-butyl-3-chloroazetidine and 1-tert-butyl-2-chloromethylaziridine", JOURNAL OF ORGANIC CHEMISTRY., vol. 35, no. 11, 1970, EASTON US, pages 3952 - 3959, XP002094428 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063168A1 (en) * 1999-04-16 2000-10-26 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
JP2009523715A (ja) * 2006-01-16 2009-06-25 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 新規殺虫剤
US8697683B2 (en) 2009-04-22 2014-04-15 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8962607B2 (en) 2009-04-22 2015-02-24 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8367653B2 (en) 2009-04-22 2013-02-05 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8399454B2 (en) 2009-04-22 2013-03-19 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8415341B2 (en) 2009-04-22 2013-04-09 Janssen Pharmaceutica, Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
US8426401B2 (en) 2009-04-22 2013-04-23 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8435977B2 (en) 2009-04-22 2013-05-07 Janssen Pharmaceutica, Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
US8445477B2 (en) 2009-04-22 2013-05-21 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8450303B2 (en) 2009-04-22 2013-05-28 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8455476B2 (en) 2009-04-22 2013-06-04 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8741887B2 (en) 2009-04-22 2014-06-03 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8362000B2 (en) 2009-04-22 2013-01-29 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8722658B2 (en) 2009-04-22 2014-05-13 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8623858B2 (en) 2009-04-22 2014-01-07 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8604017B2 (en) 2009-04-22 2013-12-10 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8691805B2 (en) 2009-04-22 2014-04-08 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8362001B2 (en) 2009-04-22 2013-01-29 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8759533B2 (en) 2010-09-03 2014-06-24 Janssen Pharmaceutica Nv Di-azetidinyl diamide as monoacylglcerol lipase inhibitors
US8759333B2 (en) 2010-09-03 2014-06-24 Janssen Pharmaceutica Nv Di-azetidinyl diamide as monoacylglycerol lipase inhibitors
US8637498B2 (en) 2010-09-27 2014-01-28 Janssen Pharmaceutica, Nv Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
US8575363B2 (en) 2010-10-22 2013-11-05 Janssen Pharmaceutica N.V. Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery

Also Published As

Publication number Publication date
WO1999019297A9 (en) 1999-07-08
AU1089599A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
WO2000063168A1 (en) Synthesis of azetidine derivatives
US10336727B2 (en) Histone demethylase inhibitors
US10807956B2 (en) Histone demethylase inhibitors
US7002036B2 (en) Synthesis of 2-alkyl amino acids
CA2133152C (en) Piperidines and piperazines with affinity for 5-ht receptors
US9611224B2 (en) Antiproliferative benzo [B] azepin-2-ones
WO1999019297A1 (en) Synthesis of azetidine derivatives
US20110275687A1 (en) Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
US20200115392A1 (en) Azetidine derivative
CN115551496A (zh) Stat抑制性化合物和组合物
EP1556378B1 (de) Acylderivate von 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-on mit neuroleptischer wirkung
WO2006115245A1 (ja) 4-エチニルイソキノリン誘導体及びこれを含有する医薬
US8299258B2 (en) Method of making piperidine derivatives
AU2019400398A1 (en) Estrogen receptor antagonist
US20230107634A1 (en) Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
CN112961081B (zh) 一种联苯甲酰胺脲类化合物及其制备方法和应用
CN109422739B (zh) 氘代的吲哚胺2,3-双加氧酶抑制剂及其应用
CN116514796A (zh) 3CLpro蛋白酶抑制剂的盐、晶型及其制备方法
WO1996032369A1 (fr) Nouveaux composes aryloxypropanolamino(phenyl)propanol
JP2006188505A (ja) インドール類の製造方法および製造中間体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-63, DESCRIPTION, REPLACED BY NEW PAGES 1-63; PAGES 64-68, CLAIMS, REPLACED BY NEW PAGES 64-68; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA